Camptothecin-based nanodrug delivery systems.

about

Camptothecin-based nanodrug delivery systems.

Item

http://www.wikidata.org/entity/Q47700115

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Camptothecin-based nanodrug delivery systems.

@en

Camptothecin-based nanodrug delivery systems.

@nl

type

Item

label

Camptothecin-based nanodrug delivery systems.

@en

Camptothecin-based nanodrug delivery systems.

@nl

prefLabel

Camptothecin-based nanodrug delivery systems.

@en

Camptothecin-based nanodrug delivery systems.

@nl

P1476

Camptothecin-based nanodrug delivery systems.

@en

P2093

Wei Zhang

http://www.w3.org/2001/XMLSchema#string

Xiaoli Liu

http://www.w3.org/2001/XMLSchema#string

Xingjie Liang

http://www.w3.org/2001/XMLSchema#string

Xinhe Xiong

http://www.w3.org/2001/XMLSchema#string

Yan Wen

http://www.w3.org/2001/XMLSchema#string

Yingze Wang

http://www.w3.org/2001/XMLSchema#string

Zhongxiao Han

http://www.w3.org/2001/XMLSchema#string

P2860

Onivyde for the therapy of multiple solid tumors

Phase I trial of poly-L-glutamate camptothecin (CT-2106) administered weekly in patients with advanced solid malignancies

Carbon nanotubes introduced into the abdominal cavity of mice show asbestos-like pathogenicity in a pilot study

Phase I and pharmacokinetic study of DE-310 in patients with advanced solid tumors.

Surface modification of gold and quantum dot nanoparticles with chitosan for bioapplications.

Phase I and pharmacokinetic (PK) study of MAG-CPT (PNU 166148): a polymeric derivative of camptothecin (CPT)

A phase II study of pegylated-camptothecin (pegamotecan) in the treatment of locally advanced and metastatic gastric and gastro-oesophageal junction adenocarcinoma.

Multifunctional inorganic nanoparticles for imaging, targeting, and drug delivery.

A phase 1 open-label, sequential dose-escalation study investigating the safety, tolerability, and pharmacokinetics of intravenous TLC388 administered to patients with advanced solid tumors.

Strategies for advancing cancer nanomedicine.

P304

363-370

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.20892/J.ISSN.2095-3941.2017.0099

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29372102

http://www.w3.org/2001/XMLSchema#string

P932

5785165

http://www.w3.org/2001/XMLSchema#string